RESUMO
Baricitinib is a Janus kinase inhibitor that has been approved by the US Food and Drugs Administration for the treatment of severe alopecia areata (AA) in adults. However, the clinical trials that demonstrated the efficacy of baricitinib in the treatment of severe AA did not include men aged > 60â years or women aged > 70â years. We retrospectively assessed the efficacy and safety of baricitinib in 14 patients aged ≥ 65â years with moderate-to-severe AA. After a mean (SD) duration of 18.5 (11.9) months, a 72% reduction in mean Severity of Alopecia Tool score from baseline was observed. Partial or complete eyebrow and eyelash hair was observed in 57% and 43% of patients, respectively. The adverse effects of baricitinib were mild. No cases of venous thromboembolism, major adverse cardiovascular events or malignancy were reported.
Assuntos
Alopecia em Áreas , Azetidinas , Purinas , Pirazóis , Índice de Gravidade de Doença , Sulfonamidas , Humanos , Azetidinas/uso terapêutico , Azetidinas/efeitos adversos , Sulfonamidas/uso terapêutico , Sulfonamidas/efeitos adversos , Alopecia em Áreas/tratamento farmacológico , Purinas/uso terapêutico , Purinas/efeitos adversos , Pirazóis/uso terapêutico , Pirazóis/efeitos adversos , Masculino , Feminino , Idoso , Estudos Retrospectivos , Resultado do Tratamento , Inibidores de Janus Quinases/uso terapêutico , Inibidores de Janus Quinases/efeitos adversos , Idoso de 80 Anos ou maisRESUMO
IMPORTANCE: Alopecia induced by classic chemotherapy affects up to 65% of patients and is usually reversible. However, there are increasing reports of persistent chemotherapy-induced alopecia (pCIA), especially for patients treated with taxane-containing chemotherapy regimens. OBJECTIVE: To analyze the clinicopathologic characteristics and response to treatment of patients with pCIA after chemotherapy for breast cancer. DESIGN, SETTING, AND PARTICIPANTS: In this case series, a retrospective evaluation was performed of patients with a diagnosis of pCIA after chemotherapy for breast cancer in 4 specialist hair clinics from November 1, 2011, to February 29, 2020. MAIN OUTCOMES AND MEASURES: Clinical, trichoscopic, and histopathologic characteristics and treatment outcomes were analyzed. For patients who presented with diffuse alopecia or diffuse rarefaction of hair over the midfrontal scalp with widening of the central part line and preservation of the frontal hairline, the Sinclair scale (grades 1-5, where 1 indicates normal hair density and 5 indicates the most severe stage of hair loss, with little or no hair in the centroparietal region) was used to assess severity. RESULTS: One hundred patients (99 women [99%]; mean age at presentation, 54.0 years [range, 29.0-74.1 years]) were included. Most patients had diffuse nonscarring alopecia (n = 39), female pattern hair loss (n = 55), or male pattern hair loss (n = 6). Six patients developed cicatricial alopecia. Taxane-containing regimens were used for most patients (92 [92%]) and were associated with more severe alopecia than regimens that did not contain taxanes (median Sinclair grade, 4 [IQR, 3-5] vs 2 [IQR, 2-2.5]; P < .001). A total of 76 of 86 patients (88%) had trichoscopic signs indistinguishable from those of androgenetic alopecia. Of 18 patients who had biopsies, 14 had androgenetic alopecia-like features, 2 had cicatricial alopecia, and 2 had features of both. Both topical and oral minoxidil, sometimes combined with antiandrogen therapy, were associated with an improvement in hair density (median Sinclair grade, 4 [IQR, 3-5] before treatment vs 3 [IQR, 2-4] after treatment; P < .001). CONCLUSIONS AND RELEVANCE: This case series outlines previously unreported features of pCIA in patients with breast cancer, including a trichoscopic description. Cosmetically significant regrowth was achieved for a significant proportion of patients with topical or systemic treatments, suggesting that pCIA may be at least partly reversible.
Assuntos
Alopecia em Áreas , Antineoplásicos , Neoplasias da Mama , Sobreviventes de Câncer , Alopecia/induzido quimicamente , Alopecia/diagnóstico , Alopecia/tratamento farmacológico , Alopecia em Áreas/tratamento farmacológico , Antineoplásicos/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Feminino , Humanos , Masculino , Estudos RetrospectivosAssuntos
Anormalidades Múltiplas/diagnóstico , Alopecia/diagnóstico , Doença de Darier/diagnóstico , Sobrancelhas/anormalidades , Anormalidades Múltiplas/patologia , Adulto , Alopecia/patologia , Doença de Darier/patologia , Dermoscopia , Diagnóstico Diferencial , Sobrancelhas/diagnóstico por imagem , Sobrancelhas/patologia , Fibrose , Humanos , MasculinoRESUMO
Introduction: Androgenetic alopecia is a common hair loss disorder affecting up to 80% of males by the age of 80. It is characterized by androgen related progressive thinning of hair in a defined pattern. It results in diminished self-esteem, reduced confidence and distress in affected men, irrespective of age or stage of baldness. An effective treatment for hair baldness is needed.Areas covered: In androgenetic alopecia, hair follicles undergo progressive miniaturization. Genetic factors and androgens are key role-players in disease pathogenesis. Herein the authors review the pharmacologic treatment of androgenetic alopecia, which involves 5 alpha reductase inhibitors, minoxidil and prostaglandins. Non-pharmacologic approaches are also explored.Expert opinion: Androgenetic alopecia progresses over time and although the current available medical treatments like finasteride and minoxidil are effective in arresting the progression of the disease, they allow only partial regrowth of hair at its best. Early treatment achieves a more optimal outcome. Non-pharmacologic treatments like PRP can be considered in patients refractory to medical treatment.Abbreviations: MPHL: male pattern hair loss; AGA: androgenetic alopecia; DHT: dihydrotestosterone; 5AR: 5-alpha-reductase; VEGF: vascular endothelial growth factor; PG's: prostaglandins (PG's); PGD2R: prostaglandin D2 receptor; VPA: valproic aid; SR: Serenoa Repens; PRP: platelet-rich plasma; PDGF: platelet derived growth factor; TGF: transforming growth factor; ERK: extracellular signal-regulated kinase; PKB: protein kinase B; LLLT: low-level laser therapy; ROS: reactive oxygen species; RCT: randomized control trial; SFRP1: secreted frizzled related protein 1; DP: dermal papilla; PDE5: phosphodiesterase 5.
Assuntos
Alopecia/tratamento farmacológico , Finasterida/uso terapêutico , Minoxidil/uso terapêutico , Prostaglandinas/uso terapêutico , Administração Oral , Administração Tópica , Alopecia/radioterapia , Agulhamento Seco , Finasterida/administração & dosagem , Cabelo/efeitos dos fármacos , Cabelo/crescimento & desenvolvimento , Humanos , Terapia com Luz de Baixa Intensidade , Masculino , Minoxidil/administração & dosagem , Prostaglandinas/administração & dosagem , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do TratamentoAssuntos
Alopecia/radioterapia , Doenças Genéticas Ligadas ao Cromossomo X/radioterapia , Ictiose/radioterapia , Lasers Semicondutores/uso terapêutico , Terapia com Luz de Baixa Intensidade/instrumentação , Dermatopatias Genéticas/radioterapia , Alopecia/etiologia , Biópsia , Doenças Genéticas Ligadas ao Cromossomo X/complicações , Humanos , Ictiose/complicações , Masculino , Couro Cabeludo/patologia , Couro Cabeludo/efeitos da radiação , Pele/patologia , Pele/efeitos da radiação , Dermatopatias Genéticas/complicações , Resultado do Tratamento , Adulto JovemRESUMO
Angiokeratoma corporis diffusum refers to symmetrical clusters of minute red papules in a "bathing trunk" distribution and is considered the cutaneous hallmark of Fabry disease. Acid sphingomyelinase deficiency is an autosomal recessive sphingolipidosis, which presents with massive hepatosplenomegaly, pulmonary infiltrates, and skeletal abnormalities. We present the unusual case of a 12-year-old girl with acid sphingomyelinase deficiency who developed characteristic lesions of angiokeratoma corporis diffusum.
Assuntos
Doença de Fabry/diagnóstico , Doença de Niemann-Pick Tipo A/diagnóstico , Criança , Dermoscopia , Diagnóstico Diferencial , Feminino , HumanosRESUMO
AIMS: The National Institute for Health and Care Excellence advocated the development of specialist skin cancer multidisciplinary teams (SSMDTs) for the management of higher risk invasive skin cancers in the UK. The interobserver variability in the histopathological assessment of primary cutaneous malignant melanoma (PCMM) is well recognised. METHODS: We evaluated the discordance rates in the assessment of the histopathological criteria of PCMM based on the eighth American Joint Committee on Cancer (AJCC) melanoma staging system and subsequent change in prognosis and management following pathology review by an SSMDT. RESULTS: 353 cases of PCMM were referred to our SSMDT between April 2015 and May 2016. Cases in which there was a discrepancy in one or more histological parameters following expert review were collected retrospectively. Of 341 eligible cases, there were 94 (27.6%) in which there was an alteration in any parameter. There was interobserver agreement in final diagnosis in 96.8%, Breslow thickness in 86.8%, ulceration in 98.2%, microsatellites in 98.5%, tumour mitotic rate in 88.9%, histological subtype in 92.4%, growth phase in 98.5%, angiolymphatic invasion in 97.7%, perineural invasion in 98.8%, regression in 95.3% and tumour-infiltrating lymphocytes in 95.0%. A corresponding change in AJCC stage occurred in 23 cases (6.7%), with a resulting change in clinical management in 10 cases (2.9%). CONCLUSIONS: Disagreements in the pathological assessment of PCMM can have significant clinical implications for a small number of patients. Our findings highlight the value of the SSMDT for high-quality care of patients with melanoma in the UK.
Assuntos
Melanoma/patologia , Variações Dependentes do Observador , Neoplasias Cutâneas/patologia , Dermatologistas , Feminino , Humanos , Linfócitos do Interstício Tumoral , Melanoma/diagnóstico , Estadiamento de Neoplasias , Patologistas , Assistência ao Paciente , Equipe de Assistência ao Paciente , Prognóstico , Encaminhamento e Consulta , Estudos Retrospectivos , Neoplasias Cutâneas/diagnóstico , Reino Unido , Melanoma Maligno CutâneoRESUMO
Primary localized cutaneous amyloidosis is a group of rare conditions where amyloid deposition is limited to the skin without systemic manifestations. Most cases are sporadic; however, mutations in the oncostatin M receptor (OSMR) and interleukin-31 receptor A (IL31RA) genes can cause a familial form of the condition in up to 10% of cases. Here, we describe a family in which 8 female individuals are affected by either macular amyloidosis or amyloidosis cutis dyschromica. To the best of our knowledge, a sex-specific expression or the coexistence of 2 different phenotypes of primary localized cutaneous amyloidosis in 1 pedigree has not yet been reported.
Assuntos
Amiloidose Familiar/patologia , Dermatopatias Genéticas/patologia , Adulto , Feminino , Humanos , Paquistão , Linhagem , FenótipoRESUMO
BACKGROUND AND AIMS: Vulval Crohn's disease (VCD) is a rare extra-intestinal cutaneous manifestation of Crohn's disease. VCD is often unrecognized and misdiagnosed and can be difficult to treat. The aim of the study was to describe the clinical presentation, associated features, and response to treatment modalities in patients with VCD. METHODS: A prospective review of patients with VCD who were referred to our specialist dermatology clinic from 2003 to 2017 was performed. Data on age at diagnosis, presenting signs, associated features, and response to treatment were collected. RESULTS: Thirty-one patients with a median age of 40 years (range 13-66 years) were identified. VCD manifested most frequently with vulval edema (77%), ulceration (35%), and fissures (39%). Eighty-one percent had active gastrointestinal disease. Oral involvement and pyoderma gangrenosum were present in 13% and 19%, respectively. Topical therapy was effective in mild VCD. Tumor necrosis factor-α inhibitors were the most effective second-line therapy, with 53% achieving complete clinical remission. Additionally, we have found compression garments and shorts to be useful adjuncts in treating vulval edema. CONCLUSIONS: Vulval Crohn's disease is a diagnostic and therapeutic challenge. We recommend consideration of tumor necrosis factor-α inhibitors at an early stage.
Assuntos
Doença de Crohn/complicações , Edema/etiologia , Úlcera Cutânea/etiologia , Doenças da Vulva/etiologia , Adolescente , Adulto , Idoso , Anti-Inflamatórios/administração & dosagem , Produtos Biológicos/administração & dosagem , Biópsia , Bandagens Compressivas , Doença de Crohn/diagnóstico , Doença de Crohn/imunologia , Doença de Crohn/terapia , Edema/diagnóstico , Edema/imunologia , Edema/terapia , Feminino , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos , Indução de Remissão , Úlcera Cutânea/diagnóstico , Úlcera Cutânea/imunologia , Úlcera Cutânea/terapia , Fatores de Tempo , Resultado do Tratamento , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/imunologia , Doenças da Vulva/diagnóstico , Doenças da Vulva/imunologia , Doenças da Vulva/terapia , Adulto JovemRESUMO
BACKGROUND: An initial study of patch testing practices across Wales, United Kingdom, showed wide variation in practice against a standardized set of guidelines and best practice recommendations. OBJECTIVES: To evaluate (i) current patch testing practice on a national level in the United Kingdom and Republic of Ireland (ROI), (ii) compliance with the current published guidelines, and (iii) the proportion of the catchment population tested by patch testing centres. METHODS: In consultation with the British Association of Dermatologists and British Society for Cutaneous Allergy, proformas addressing clinical guidelines and best practice recommendations were sent to all dermatology units in the United Kingdom and ROI. RESULTS: Ninety one of 325 centres (28%) performed patch testing. The optimum proportion of annual tests was not being achieved in the United Kingdom and ROI. The range tested varied between 1:1200 and 1:1600. CONCLUSIONS: Most centres achieved a high level of best practice outcomes. Shortcomings were found in the recording of minimum data, benchmarking, and attendance at meetings. We suggest that the findings of this study should be used as evidence to help improve services locally.
Assuntos
Dermatite Alérgica de Contato/diagnóstico , Dermatologia/normas , Programas de Rastreamento/normas , Testes do Emplastro/normas , Dermatite Atópica/diagnóstico , Humanos , Irlanda , Padrões de Prática Médica , Reino UnidoAssuntos
Antineoplásicos/uso terapêutico , Dermatoses Faciais/diagnóstico por imagem , Dermatoses da Mão/tratamento farmacológico , Hidroxiureia/efeitos adversos , Ceratose Actínica/tratamento farmacológico , Antineoplásicos/efeitos adversos , Diterpenos/uso terapêutico , Feminino , Fluoruracila/uso terapêutico , Humanos , Imiquimode/uso terapêutico , Pessoa de Meia-Idade , Trombocitemia Essencial/tratamento farmacológico , Falha de TratamentoRESUMO
The eruptive disseminated form of Spitz nevi (EDSN) is the rarest variant, is cosmetically disabling, and has a poorly documented natural history. We report the case of a 4-year-old boy with more than 100 Spitz nevi that have significantly regressed 8 years after onset. There is no satisfactory treatment for EDSN. There have been no reports of supervening malignancy. Our case illustrates the possibility of regression of EDSN, corroborating long-term observation as a safe and acceptable management option.